American Society of Hirudotherapy

Chronic Idiopathic Urticaria (Investigational Adjunct)

Investigational adjunct for chronic spontaneous urticaria refractory to high-dose H1 antihistamines; omalizumab, cyclosporine, and step-up guideline-directed therapy remain evidence-based.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 10, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for chronic idiopathic / spontaneous urticaria. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
What evidence exists?
Tier C (investigational). No controlled trial was identified; the only report found is a single-patient case report in which leeches were combined with oral medicines. Evidence-based first-line management is second-generation H1 antihistamines at standard doses, uptitrated up to fourfold if needed, addition of H2 antihistamine or leukotriene receptor antagonist, omalizumab (FDA-approved for chronic spontaneous urticaria refractory to antihistamines), and for refractory disease cyclosporine or other immunomodulators under specialist supervision.
Main risks
  • Bleeding from each bite site for 6 to 10 hours after the leech detaches
  • Iron-deficiency anemia from cumulative blood loss across multiple sessions
  • Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
  • Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
  • Small Y-shaped bite marks or skin colour changes at the bite sites, which usually fade over weeks to months
  • Local pain, bruising, swelling, or itching for 1 to 3 days after each session
  • Allergic reactions to leech proteins may be misinterpreted as urticaria flare
  • Risk of anaphylaxis (already concerning in this population)
  • Triggering urticarial flare from cutaneous trauma
Who should not consider this
  • Patients who have not had fourfold-uptitrated H1 antihistamine for 4+ weeks
  • Patients eligible for omalizumab who have not been offered it
  • Patients with known anaphylaxis to leeches or other arthropod proteins
  • Patients with autoimmune urticaria with positive autologous serum skin test (these may need immunomodulators)
  • Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran or heparin (daily aspirin alone is not a contraindication: tell your doctor, who starts with fewer leeches)
  • People with hemophilia or any other inherited bleeding disorder
  • Patients with anemia
What to ask your clinician
  • Have I been on fourfold-uptitrated H1 antihistamine?
  • Has omalizumab — FDA-approved for chronic spontaneous urticaria — been considered?
  • Have triggers and physical urticaria types been ruled out?
  • What is the published evidence base for leeches in CIU?
  • What is the plan if my urticaria flares severely from bites?
  • What is the anaphylaxis-prevention plan?
When to seek urgent care
  • Bleeding from a bite site that soaks through more than one dressing per hour
  • Bleeding that continues more than 24 hours after the leech detached
  • Spreading redness, warmth, swelling, pus, or red streaks around any bite site
  • Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
  • Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
  • Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
  • Severe widespread hives with throat swelling, breathing difficulty, lightheadedness, or vomiting (anaphylaxis — emergency)
  • Sudden severe abdominal pain or syncope

What this does NOT mean

  • It does not mean leech therapy is FDA-cleared for urticaria — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
  • It does not replace fourfold-uptitrated H1 antihistamines or omalizumab.
  • It does not modify the underlying mast cell pathology.
  • It risks anaphylaxis from leech proteins in a population already prone to allergic reactions.
  • It does not have controlled-trial evidence in CIU: none was identified, and the only report found is a single case report in which leeches were combined with oral medicines.

Clinical Profile

Category
Dermatological
ICD-10
L50.1, L50.8, L50.9
Safety tier
High

Evidence Summary

Chronic spontaneous (idiopathic) urticaria is daily or near-daily wheals with or without angioedema persisting more than 6 weeks. Step-up management per international guideline: second-generation H1 antihistamine at standard dose, then up to 4x dose, then add omalizumab (anti-IgE), then cyclosporine for refractory disease. Short corticosteroid bursts for severe flares only. Trigger identification is rarely successful in true idiopathic disease. No controlled trial of hirudotherapy for chronic urticaria was identified. The only clinical report found is a single case report (Subramanian and colleagues, 2025): a 37-year-old man with urticaria refractory to antihistamines and corticosteroids improved after Siddha leech sessions together with oral Siddha medicines, so the contribution of the leeches cannot be separated. Direct application to active wheals is contraindicated, and placement on lesion-free skin may itself trigger urticarial reaction.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Active urticarial flare or angioedema
  • Prior anaphylaxis to insect or arthropod bites
  • Concurrent ACE inhibitor or NSAID-induced angioedema
  • Cold urticaria, cholinergic urticaria, or other physical urticarias (placement triggers flare)
  • Pediatric or geriatric patient with cardiovascular disease (anaphylaxis risk)

Related Conditions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.